Everyone should just take a step back and calm down.Everyone should just take a deep breath. Yesterday was a big disappointment but most of us who have been following the MCNA story closely knew that Telesta staff had not done a good job presenting their data at the Ad Comm and we knew FDA approval was a 50/50 chance. We were hoping the global BCG shortage would play into the FDA decision and that their earlier involvement in the MCNA study design meant they would overlook the study's shortcomings. Unfortunately, this didn't happen. But MCNA still offers an excellent alternative for this particular group of bladder cancer patients and may even be of use in a wider group of patients in the long run especially if BCG continues in short supply. This is a good take on what happened yesterday and what the future might look like: https://www.stockhouse.com/news/newswire/2016/02/02/telesta-therapeutics-t-tst-slammed-down-76-after-fda-delay